Common use of Conduct of Trial Clause in Contracts

Conduct of Trial. The Institution and the Investigator shall conduct the Trial in accordance with the Protocol, the opinion of the ethics committee(s), this Agreement and any additional reasonable requirements notified by Biogen to the Investigator. The Investigator and the Institution acknowledge that Biogen, and its affiliates need to adhere to the provisions of (i) the Xxxxxxx Xxx 0000 of the United Kingdom (Bribery Act); (ii) the Foreign Corrupt Practices Xxx 0000 of the United States of America (FCPA) and (iii) any other applicable anti-corruption legislation (together the Applicable Anti-Corruption Legislation). A summary of the key principles underlying the Bribery Act and the FCPA is set out in Schedule C. The Institution and the Investigator shall not and shall not permit or induce employees, agents, consultants or other representatives, whether directly or indirectly, to engage in any activity that is prohibited by the Applicable Anti-Corruption Legislation including bribery, kickbacks, payoffs or other corrupt business practices. Furthermore, the Institution and the Investigator shall conduct the Trial in accordance with all national and supranational legislation, regulations and guidance notes relevant to the jurisdiction in which the Trial is being conducted, including, but not limited to:

Conduct of Trial. The Institution and the Investigator shall conduct the Trial in accordance with the Protocol, the opinion of the ethics committee(s), this Agreement and any additional reasonable requirements notified by Biogen to the Investigator. The Investigator and the Institution acknowledge that Biogen, and its affiliates need to adhere to the provisions of (i) the Xxxxxxx Xxx 0000 of the United Kingdom (“Bribery Act”); (ii) the Foreign Corrupt Practices Xxx 0000 of the United States of America (“FCPA”) and (iii) any other applicable anti-corruption legislation (together the “Applicable Anti-Corruption Legislation”). A summary of the key principles underlying the Bribery Act and the FCPA is set out in Schedule C. The Institution and the Investigator shall not and shall not permit or induce employees, agents, consultants or other representatives, whether directly or indirectly, to engage in any activity that is prohibited by the Applicable Anti-Corruption Legislation including bribery, kickbacks, payoffs or other corrupt business practices. Furthermore, the Institution Institution, Biogen and the Investigator shall conduct the Trial in accordance with all national and supranational legislation, regulations and guidance notes relevant to the jurisdiction in which the Trial is being conducted, including, but not limited to:

Conduct of Trial. The Institution and the Investigator shall conduct the Trial in accordance with the Protocol, the opinion of the ethics committee(s), this Agreement and any additional reasonable requirements notified by Biogen to the Investigator. The Investigator and the Institution acknowledge that Biogen, and its affiliates need to adhere to the provisions of (i) the Xxxxxxx Xxx 0000 of the United Kingdom (“Bribery Act”); (ii) the Foreign Corrupt Practices Xxx 0000 of the United States of America (“FCPA”) and (iii) any other applicable anti-corruption legislation (together the “Applicable Anti-Corruption Legislation”). A summary of the key principles underlying the Bribery Act and the FCPA is set out in Schedule C. The Institution and the Investigator shall not and shall not permit or induce employees, agents, consultants or other representatives, whether directly or indirectly, to engage in any activity that is prohibited by the Applicable Anti-Anti- Corruption Legislation including bribery, kickbacks, payoffs or other corrupt business practices. Furthermore, the Institution and the Investigator shall conduct the Trial in accordance with all national and supranational legislation, regulations and guidance notes relevant to the jurisdiction in which the Trial is being conducted, including, but not limited to:

Conduct of Trial. The Institution and the Principal Investigator shall conduct the Trial in accordance with the Protocol, the opinion of the ethics committee(s), this Agreement and any additional reasonable requirements notified by Biogen Hexal directly or through CRO to the Principal Investigator. The Principal Investigator and the Institution acknowledge that Biogen, Hexal directly or through CRO and its affiliates need to adhere to the provisions of (i) the Xxxxxxx Xxx 0000 Bribery Act 2010 of the United Kingdom (Bribery Act); (ii) the Foreign Corrupt Practices Xxx 0000 Act 1977 of the United States of America (FCPA) and (iii) any other applicable anti-anti- corruption legislation (together the Applicable Anti-Anti- Corruption Legislation). A summary of the key principles underlying the Bribery Act and the FCPA is set out in Schedule C. The Institution and the Principal Investigator shall not and shall not permit or induce employees, agents, consultants or other representatives, whether directly or indirectly, to engage in any activity that is prohibited by the Applicable Anti-Corruption Legislation including bribery, kickbacks, payoffs or other corrupt business practices. Furthermore, the Institution and the Principal Investigator shall conduct the Trial in accordance with all national and supranational legislation, regulations and guidance notes relevant to the jurisdiction in which the Trial is being conducted, including, but not limited to:: (i) the Declaration of Helsinki of the World Medical Association, "Ethical Principles for Medical Research Involving Human Subjects" as amended from time to time, (c)